Revolution Medicines Management
Management criteria checks 4/4
Revolution Medicines' CEO ist Mark Goldsmith , ernannt in Nov 2014, hat eine Amtszeit von 9.08 Jahren. Die jährliche Gesamtvergütung beträgt $7.22M , bestehend aus 8.4% Gehalt und 91.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.37% der Aktien des Unternehmens, im Wert von $14.63M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.5 Jahre bzw. 7 Jahre.
Key information
Mark Goldsmith
Chief executive officer
US$7.2m
Total compensation
| CEO salary percentage | 8.4% |
| CEO tenure | 9.4yrs |
| CEO ownership | 0.4% |
| Management average tenure | 5.9yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09
Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Revolution Medicines to raise up to $200M in stock offering
Jul 19Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 11We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Mar 31Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Dec 16What Does The Future Hold For Revolution Medicines, Inc. (NASDAQ:RVMD)? These Analysts Have Been Cutting Their Estimates
Aug 17Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Aug 03Revolution Medicines EPS misses by $0.01, beats on revenue
May 10Revolution Medicines expects no data from Amgen-sponsored clinical trial for RMC-4630
Apr 30We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Apr 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$436m |
| Sep 30 2023 | n/a | n/a | -US$331m |
| Jun 30 2023 | n/a | n/a | -US$296m |
| Mar 31 2023 | n/a | n/a | -US$259m |
| Dec 31 2022 | US$7m | US$607k | -US$249m |
| Sep 30 2022 | n/a | n/a | -US$245m |
| Jun 30 2022 | n/a | n/a | -US$224m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$8m | US$581k | -US$187m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$126m |
| Dec 31 2020 | US$2m | US$554k | -US$110m |
| Sep 30 2020 | n/a | n/a | -US$95m |
| Jun 30 2020 | n/a | n/a | -US$85m |
| Mar 31 2020 | n/a | n/a | -US$71m |
| Dec 31 2019 | US$5m | US$504k | -US$62m |
| Sep 30 2019 | n/a | n/a | -US$57m |
| Dec 31 2018 | US$1m | US$490k | -US$49m |
Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD7.22M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD6.59M).
Entschädigung vs. Einkommen: MarkDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
CEO
Mark Goldsmith (61 yo)
9.4yrs
Tenure
US$7,217,839
Compensation
Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 9.4yrs | US$7.22m | 0.38% $ 19.7m | |
| Chief Financial Officer | 5.7yrs | US$1.95m | 0.025% $ 1.3m | |
| Chief Operating Officer | 5.5yrs | US$3.08m | 0.028% $ 1.4m | |
| President of Research & Development | 7.1yrs | US$3.08m | 0.10% $ 5.2m | |
| Executive Vice President of Clinical Development | 6.1yrs | US$1.79m | 0.013% $ 691.2k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Chief Information Officer | no data | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Affairs | no data | no data | no data | |
| Senior VP | 1.6yrs | no data | 0.0033% $ 169.6k |
5.9yrs
Average Tenure
52yo
Average Age
Erfahrenes Management: Das Managementteam von RVMD ist erfahren und erfahren (durchschnittliche Amtszeit: 5.5 Jahre).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 9.4yrs | US$7.22m | 0.38% $ 19.7m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Senior Advisor & Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Lead Independent Director | 9.4yrs | US$364.84k | 1.41% $ 73.0m | |
| Senior Advisor & Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Senior Advisor & Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Independent Director | 1.8yrs | US$792.72k | 0.032% $ 1.7m | |
| Independent Director | 6.1yrs | no data | no data | |
| Independent Director | 9.1yrs | US$337.06k | 0.039% $ 2.0m | |
| Senior Advisor & Member of Scientific Advisory Board | 7.3yrs | no data | no data |
7.3yrs
Average Tenure
51yo
Average Age
Erfahrener Vorstand: RVMDDie Vorstandsmitglieder gelten als erfahren (7 Jahre durchschnittliche Amtszeit).